Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008297 | 0.84 | PDE10A (0.45) | TLR7DHODHPDE10ANPC1RAB9A | |
| SCHEMBL4009284 | 0.83 | DRD1 (0.40) | LMNASMN1; SMN2PDE10ASSTR4SSTR1 | |
| SCHEMBL482170 | 0.82 | GAA (0.46) | LMNASMN1; SMN2PDE10ANPC1RAB9A | |
| SCHEMBL20428065 | 0.79 | PDE10A (0.32) | LMNASMN1; SMN2PDE10ANPC1RAB9A | |
| SCHEMBL20428062 | 0.79 | ALDH1A1 (0.34) | LMNASMN1; SMN2PDE10ANPC1RAB9A | |
| SCHEMBL23934738 | 0.79 | ALDH1A1 (0.37) | LMNASMN1; SMN2PDE10AALDH1A1DRD1 | |
| SCHEMBL1933518 | 0.79 | SCN9A (0.41) | LMNASMN1; SMN2SSTR4NPC1RAB9A | |
| SCHEMBL3878940 | 0.78 | PDE10A (0.43) | LMNASMN1; SMN2PDE10ANPC1RAB9A | |
| SCHEMBL15473322 | 0.77 | CBFB (0.42) | TLR7DHODHSSTR4 | |
| SCHEMBL21771191 | 0.76 | PDE10A (0.36) | PDE10ARAB9AALDH1A1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398119-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2025043225-A2 | DEGRADERS OF CYCLIN-DEPENDENT KINASE 2 | GENENTECH, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-17 | — | — | US | disclosed |
| US-11958865-B1 | Leucine-rich repeat kinase 2 (LRRK2) inhibitors | H. LUNDBECK A/S (DK) | 2024-04-16 | — | — | US | disclosed |
| WO-2024056775-A1 | MACROCYCLIC LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-03-21 | — | — | WO | disclosed |
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | MEDIVIR AB (SE) | 2024-02-22 | — | — | US | disclosed |
| EP-4308566-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | Tango Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425656-A | Purine derivatives as anticancer agents | 探戈医药股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-112154145-B | Piperazine azaspiro derivatives | 辉瑞大药厂 | 2023-10-17 | — | — | CN | disclosed |
| EP-4219464-A1 | PIPERAZINE AZASPIRO DERIVAVES | Pfizer Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | PFIZER INC. | 2023-06-22 | — | — | US | disclosed |
| EP-3768669-B1 | PIPERAZINE AZASPIRO DERIVAVES | PFIZER (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11524954-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2022197892-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | TANGO THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20210024497-A1 | PIPERAZINE AZASPIRO DERIVAVES | PFIZER INC. | 2021-01-28 | — | — | US | disclosed |
| EP-3768669-A1 | PIPERAZINE AZASPIRO DERIVAVES | Pfizer Inc (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-112154145-A | Piperazine azaspiro derivatives | 辉瑞大药厂 | 2020-12-29 | — | — | CN | disclosed |
| WO-2019183636-A1 | PIPERAZINE AZASPIRO DERIVAVES | PFIZER INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| CN-109843891-A | Oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors | 勃林格殷格翰国际有限公司 | 2019-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | CHRM1, CHRM2, CHRM5 | TLR7 2866/4885DHODH 1078/4885CGAS 1343/4885 |
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | RRM2, TYMP, PNP | TLR7 2485/4885DHODH 572/4885CGAS 820/4885 |
| US-12398119-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | TLR7 2866/4885DHODH 1078/4885CGAS 1343/4885 |
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | LRRK2, PARK7, PINK1 | TLR7 3659/4885DHODH 3852/4885CGAS 2062/4885 |
| US-11958865-B1 | Leucine-rich repeat kinase 2 (LRRK2) inhibitors | LRRK2, PARK7, PINK1 | TLR7 3659/4885DHODH 3852/4885CGAS 2062/4885 |
| US-11524954-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | TLR7 2866/4885DHODH 1078/4885CGAS 1343/4885 |
| US-20210024497-A1 | PIPERAZINE AZASPIRO DERIVAVES | CHRM1, CHRM2, CHRM5 | TLR7 2643/4885DHODH 877/4885CGAS 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.